Abgenix Appoints Donald R. Joseph as Senior Vice President, General Counsel and Secretary
Abgenix, Inc. announced the appointment of Donald R. Joseph as Senior Vice President, General Counsel and Secretary. Mr. Joseph's appointment follows the departure of Susan L. Thorner, who resigned earlier this year to pursue other opportunities.
Before joining Abgenix, Mr. Joseph was the co-founder of Alekta Group, LLC, a specialty pharmaceutical consulting group and pharmaceutical development company. Prior to Alekta he was the Executive Vice President, Commercial Development of Amarin Corp. and the Executive Vice President, Legal and Commercial Development for Amarin Pharmaceuticals, its U.S. subsidiary, for three years. He was responsible for U.S. in-licensing and product acquisition transactions, commercial transition for acquired products, U.S. legal affairs, human resources and administration. From 1998 until 2001, Mr. Joseph worked at Elan Pharmaceuticals, most recently as Senior Vice President for commercial and legal affairs. Following Elan's acquisition of Athena Neurosciences, Inc. in 1996, he served as Vice President and General Counsel for Athena. From 1978 until 1993, Mr. Joseph practiced law with law firms in Oklahoma, San Francisco and San Diego. Before joining Athena Neurosciences in 1994, he was a partner in the San Francisco office of Baker & McKenzie, a prominent international law firm.
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
Positive Results in Proof-of-Concept Study with Sustained Release Treatment for Uveitis
Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan - Abbott will retain its branded generics pharmaceuticals business in emerging markets
Stanford researchers explore link between human birth defect syndrome, cancer metastasis
Asia-Pacific continues to drive global healthcare investment, innovation and growth ASEAN - A US$150 billion healthcare market by 2017, says Frost & Sullivan
Pharmacogenomics study finds rare gene variants critical for personalized drug treatment
Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection
Evolva shareholders approve all Board proposals in AGM: Green light for Abunda acquisition
Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP and CAP-T Technology
